AbbVie Q3 FY25: where the revenue came from and where it went
The whole income statement of AbbVie for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Nov 4, 2025
Revenue$15.78B
+9% year over year
Gross profit$10.47B
66% margin
Operating profit$1.90B
12% margin
Net profit$0.19B
1% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 15.78 | 100% | +9% |
| Skyrizi | 4.71 | 30% | +47% |
| Neuroscience | 2.84 | 18% | +20% |
| Rinvoq | 2.18 | 14% | +35% |
| Oncology | 1.67 | 11% | |
| Aesthetics | 1.19 | 8% | −4% |
| Other revenue | 1.18 | 7% | |
| Other key products | 1.01 | 6% | +15% |
| Humira | 0.99 | 6% | −55% |
| Cost of revenue | −5.30 | 34% | |
| Gross profit | 10.47 | 66% margin | −4pp |
| SG&A | −3.57 | 22% | −6pp |
| Other | −5.00 | 32% | +0pp |
| Operating profit | 1.90 | 12% margin | −14pp |
| Interest & other costs | −1.19 | ||
| Tax | −0.53 | ||
| Net profit | 0.19 | 1% margin | −10pp |
181 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest